Cargando…

BNT162b2 mRNA COVID-19 Vaccine Does Not Impact the Honeymoon Phase in Type 1 Diabetes: A Case Report

Type 1 diabetes (T1D), which is caused by the autoimmune destruction of insulin-secreting pancreatic beta cells, represents a high-risk category requiring COVID-19 vaccine prioritization. Although COVID-19 vaccination can lead to transient hyperglycemia (vaccination-induced hyperglycemia; ViHG), its...

Descripción completa

Detalles Bibliográficos
Autores principales: Infante, Marco, Fabbri, Andrea, Padilla, Nathalia, Pacifici, Francesca, Di Perna, Pasquale, Vitiello, Laura, Feraco, Alessandra, Giuliano, Maria, Passeri, Marina, Caprio, Massimiliano, Ricordi, Camillo, Della-Morte, David, Uccioli, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319173/
https://www.ncbi.nlm.nih.gov/pubmed/35891261
http://dx.doi.org/10.3390/vaccines10071096
_version_ 1784755484899672064
author Infante, Marco
Fabbri, Andrea
Padilla, Nathalia
Pacifici, Francesca
Di Perna, Pasquale
Vitiello, Laura
Feraco, Alessandra
Giuliano, Maria
Passeri, Marina
Caprio, Massimiliano
Ricordi, Camillo
Della-Morte, David
Uccioli, Luigi
author_facet Infante, Marco
Fabbri, Andrea
Padilla, Nathalia
Pacifici, Francesca
Di Perna, Pasquale
Vitiello, Laura
Feraco, Alessandra
Giuliano, Maria
Passeri, Marina
Caprio, Massimiliano
Ricordi, Camillo
Della-Morte, David
Uccioli, Luigi
author_sort Infante, Marco
collection PubMed
description Type 1 diabetes (T1D), which is caused by the autoimmune destruction of insulin-secreting pancreatic beta cells, represents a high-risk category requiring COVID-19 vaccine prioritization. Although COVID-19 vaccination can lead to transient hyperglycemia (vaccination-induced hyperglycemia; ViHG), its influence on the course of the clinical remission phase of T1D (a.k.a. “honeymoon phase”) is currently unknown. Recently, there has been an increasing concern that COVID-19 vaccination may trigger autoimmune phenomena. We describe the case of a 24-year-old young Italian man with T1D who received two doses of the BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine during a prolonged honeymoon phase. He experienced a transient impairment in glucose control (as evidenced by continuous glucose monitoring) that was not associated with substantial changes in stimulated C-peptide levels and islet autoantibody titers. Nonetheless, large prospective studies are needed to confirm the safety and the immunometabolic impact of the BNT162b2 vaccine in T1D patients during the honeymoon phase. Thus far, T1D patients who are going to receive COVID-19 vaccination should be warned about the possible occurrence of transient ViHG and should undergo strict postvaccination surveillance.
format Online
Article
Text
id pubmed-9319173
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93191732022-07-27 BNT162b2 mRNA COVID-19 Vaccine Does Not Impact the Honeymoon Phase in Type 1 Diabetes: A Case Report Infante, Marco Fabbri, Andrea Padilla, Nathalia Pacifici, Francesca Di Perna, Pasquale Vitiello, Laura Feraco, Alessandra Giuliano, Maria Passeri, Marina Caprio, Massimiliano Ricordi, Camillo Della-Morte, David Uccioli, Luigi Vaccines (Basel) Case Report Type 1 diabetes (T1D), which is caused by the autoimmune destruction of insulin-secreting pancreatic beta cells, represents a high-risk category requiring COVID-19 vaccine prioritization. Although COVID-19 vaccination can lead to transient hyperglycemia (vaccination-induced hyperglycemia; ViHG), its influence on the course of the clinical remission phase of T1D (a.k.a. “honeymoon phase”) is currently unknown. Recently, there has been an increasing concern that COVID-19 vaccination may trigger autoimmune phenomena. We describe the case of a 24-year-old young Italian man with T1D who received two doses of the BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine during a prolonged honeymoon phase. He experienced a transient impairment in glucose control (as evidenced by continuous glucose monitoring) that was not associated with substantial changes in stimulated C-peptide levels and islet autoantibody titers. Nonetheless, large prospective studies are needed to confirm the safety and the immunometabolic impact of the BNT162b2 vaccine in T1D patients during the honeymoon phase. Thus far, T1D patients who are going to receive COVID-19 vaccination should be warned about the possible occurrence of transient ViHG and should undergo strict postvaccination surveillance. MDPI 2022-07-08 /pmc/articles/PMC9319173/ /pubmed/35891261 http://dx.doi.org/10.3390/vaccines10071096 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Infante, Marco
Fabbri, Andrea
Padilla, Nathalia
Pacifici, Francesca
Di Perna, Pasquale
Vitiello, Laura
Feraco, Alessandra
Giuliano, Maria
Passeri, Marina
Caprio, Massimiliano
Ricordi, Camillo
Della-Morte, David
Uccioli, Luigi
BNT162b2 mRNA COVID-19 Vaccine Does Not Impact the Honeymoon Phase in Type 1 Diabetes: A Case Report
title BNT162b2 mRNA COVID-19 Vaccine Does Not Impact the Honeymoon Phase in Type 1 Diabetes: A Case Report
title_full BNT162b2 mRNA COVID-19 Vaccine Does Not Impact the Honeymoon Phase in Type 1 Diabetes: A Case Report
title_fullStr BNT162b2 mRNA COVID-19 Vaccine Does Not Impact the Honeymoon Phase in Type 1 Diabetes: A Case Report
title_full_unstemmed BNT162b2 mRNA COVID-19 Vaccine Does Not Impact the Honeymoon Phase in Type 1 Diabetes: A Case Report
title_short BNT162b2 mRNA COVID-19 Vaccine Does Not Impact the Honeymoon Phase in Type 1 Diabetes: A Case Report
title_sort bnt162b2 mrna covid-19 vaccine does not impact the honeymoon phase in type 1 diabetes: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319173/
https://www.ncbi.nlm.nih.gov/pubmed/35891261
http://dx.doi.org/10.3390/vaccines10071096
work_keys_str_mv AT infantemarco bnt162b2mrnacovid19vaccinedoesnotimpactthehoneymoonphaseintype1diabetesacasereport
AT fabbriandrea bnt162b2mrnacovid19vaccinedoesnotimpactthehoneymoonphaseintype1diabetesacasereport
AT padillanathalia bnt162b2mrnacovid19vaccinedoesnotimpactthehoneymoonphaseintype1diabetesacasereport
AT pacificifrancesca bnt162b2mrnacovid19vaccinedoesnotimpactthehoneymoonphaseintype1diabetesacasereport
AT dipernapasquale bnt162b2mrnacovid19vaccinedoesnotimpactthehoneymoonphaseintype1diabetesacasereport
AT vitiellolaura bnt162b2mrnacovid19vaccinedoesnotimpactthehoneymoonphaseintype1diabetesacasereport
AT feracoalessandra bnt162b2mrnacovid19vaccinedoesnotimpactthehoneymoonphaseintype1diabetesacasereport
AT giulianomaria bnt162b2mrnacovid19vaccinedoesnotimpactthehoneymoonphaseintype1diabetesacasereport
AT passerimarina bnt162b2mrnacovid19vaccinedoesnotimpactthehoneymoonphaseintype1diabetesacasereport
AT capriomassimiliano bnt162b2mrnacovid19vaccinedoesnotimpactthehoneymoonphaseintype1diabetesacasereport
AT ricordicamillo bnt162b2mrnacovid19vaccinedoesnotimpactthehoneymoonphaseintype1diabetesacasereport
AT dellamortedavid bnt162b2mrnacovid19vaccinedoesnotimpactthehoneymoonphaseintype1diabetesacasereport
AT uccioliluigi bnt162b2mrnacovid19vaccinedoesnotimpactthehoneymoonphaseintype1diabetesacasereport